marginal zone lymphoma
AACR 2019: 91% of patients with marginal zone lymphoma respond to umbralisib
Umbralisib, a small-molecule inhibitor that targets PI3K-delta, is safe and efficacious for patients with relapsed/refractory marginal zone lymphoma. This an interim analysis of the phase II clinical trial UNITY-NHL shows.
